ENVIRONMENTAL EXPOSURE TO FUNCTION OF LUNG EPITHELIAL STEM CELL BIOLOGY
Dr Clare Weeden
Laboratory Head
The Walter and Eliza Hall Institute of Medical Research (WEHI)
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | March 2025
Dr Clare Weeden has recently commenced as a Laboratory Head at WEHI in 2025, supported by the CSL Centenary Fellowship.
Dr Weeden specialises in lung epithelial cell biology in the context of homeostasis, inflammation, and lung cancer, particularly in people who don’t smoke. Her work endeavours to understand how past environmental exposures shape the responses of lung cells and the molecular mechanisms underlying this cellular recall, with the aim to develop novel early detection strategies for lung disease.
Dr Weeden completed her PhD studying lung squamous cell carcinoma initiation and treatment with Professor Marie-Liesse Asselin-Labat at WEHI, where she discovered distinct DNA repair abilities in lung stem cells that enabled their susceptibility to cancer, published in PLOS Biology.
Dr Weeden conducted postdoctoral research at WEHI and found that the pre-existing lung immune microenvironment had lasting effects on tumour immunogenicity and response to immunotherapy, published in Cancer Cell. She then continued her research on early tumour biology in Professor Charles Swanton’s laboratory at the Francis Crick Institute, London, where she was part of a team discovery that air pollution triggers inflammatory signalling in the lung that awakens previously dormant cells to initiate lung cancers in people who don’t smoke, published in Nature.
Dr Weeden is the past recipient of prestigious fellowships (Marie Sklodowska Curie Actions, Lung Foundation Australia Deep Manchanda Early Career Fellowship), research grants (Cancer Research UK, Mark Foundation, Cure Cancer/Cancer Australia) and has published 36 research publications with over 1000 citations.
Source: supplied
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
New models of care and value in General Practice
Dr Michael Wright is a GP, health economist and health services researcher. Dr Wright currently works as a portfolio GP, combining clinical practice with strategic appointments (most recently with RACGP, Central and Eastern Sydney Primary Health Network, Avant Mutual the Australian Institute of Health and Welfare) and academic research analysing the effects of current health policy on the quality and performance of primary care.
-
Developing upper limb motor biomarkers of dementia
Kaylee is currently a research fellow with the Wicking Dementia Research and Education Centre at the University of Tasmania. She has recently submitted her PhD thesis, reporting the findings of her research on developing upper limb motor biomarkers of dementia. She has postgrad degrees in physiotherapy and experience working in the community and aged care across Tasmania for several years, where she worked with people with dementia.
